Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Eisai
Eisai
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Regulatory
FDA grants landmark approval for Alzheimer’s treatment
LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory
AbbVie and Eisai launch online Humira support tool service
The free-of-charge service assists patients on Humira therapy by delivering support tools to their home or other requested location
Finance
Eisai and Fuji Yakuhin sign ASEAN distribution agreement for gout therapy
Hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout
Research & Development
Eisai and Biogen announce Phase IV Alzheimer's study design
The companies will be evaluating the long-term effectiveness and safety data of Biogen's Alzheimer's therapy, Aduhelm
Regulatory
Eisai and Merck combination cancer therapy approved by FDA
The approval for this population is based on results from a Phase III Study 309/KEYNOTE-775 trial
Research & Development
Eisai makes major investments in drug creation
Platform will be established to combine Eisaid know-how with external big data and genomic data for drug innovation in neurology and oncology
Ingredients
Therapeutics: lemborexant for sleep disorders
About a third of adults suffer from the symptoms of insomnia, such as difficulty falling asleep, staying asleep or both
Subscribe now